August 27th 2025
A novel use of minor salivary glands offers lasting relief and visual improvement.
IOL filters, protects against harmful UV, blue-light hazard
October 1st 2003London-Exposure of the retina to excessive blue light is hazardous to the pigment epithelial cells and may underlie the increase in the prevalence of age-related macular degeneration (AMD) in individuals in the eighth and ninth decades of life.
Read More
Hybrid design brings best of both worlds in IOL edges
October 1st 2003The Clariflex and Sensar AR40e IOLs (AMO) are physician-friendly implants that provide patients with unsurpassed optical performance because of their proprietary OptiEdge (AMO) design, agree cataract surgeons who favor the OptiEdge IOLs.
Read More
Aspheric lens helps improve quality of vision
October 1st 2003Visual performance after cataract surgery is superior in eyes with the aspheric IOL implanted compared with other commonly used foldable implants, according to the results of a blinded, prospective, randomized study presented by Robert M. Kershner, MD, FACS.
Read More
Exciting progress continues to be made in IOL technology. However, as researchers develop new materials and designs, Nick Mamalis, MD, cautioned that care must to be taken to avoid revisiting old problems so that, as the Barenaked Ladies song title says, "Everything Old is New Again."
Read More
Vision outcomes create optimistic expectation for spectacle independence
October 1st 2003Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.
Read More
Presbyopic patients almost spectacle-free after lens exchange procedure
October 1st 2003Mainz, Germany-Refractive lens exchange with implantation of a foldable, multifocal IOL is a safe, effective, and stable surgical option for the treatment of hyperopia and myopia in the presbyopic population.
Read More
Hydrophilic IOL yields low incidence of Nd:YAG capsulotomy
October 1st 2003New York-The 1-year follow-up of the Hydroview IOL (Bausch & Lomb) indicates that the lens is safe and provides excellent postoperative visual outcomes, a low incidence of Nd:YAG capsulotomy, and no cases of decentration, according to Douglas Grayson, MD, FACS.
Read More
European study's interim results favorable for myopic PRL
September 15th 2003San Francisco-An interim analysis of data from an ongoing European multicenter study of the Phakic Refractive Lens (PRL, CIBA Vision/Medennium) indicates that the posterior chamber implant is a safe, effective, and predictable method for correcting high myopia, said Bo Philipson, MD, PhD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Read More
Silicone punctum plugs improve ocular surface in dry eye
September 15th 2003Fort Lauderdale, FL-Blocking the canaliculus with silicone punctal plugs has been shown to improve the stability of the tear film, decrease the ocular surface staining scores and squamous metaplasia grades, and increase the goblet cell density, according to Dilek Dursun, MD.
Read More
Cosmetic botulinum toxin appealing to patients, physicians
September 1st 2003Kansas City, KS-Incorporating cosmetic botulinum toxin type A (Botox, Botox Cosmetic, Allergan) treatment into an ophthalmic practice's realm of services can be very satisfying for patients and the practitioner, said Jemshed A. Khan, MD.
Read More
NSAID helps reduce pain after cataract, refractive surgery
August 15th 2003Duluth, GA-Diclofenac sodium ophthalmic solution (Voltaren, Novartis Ophthalmics) is a nonsteroidal anti-inflammatory drug (NSAID) with a proven track record. It is the drug of choice to relieve pain following cataract or refractive surgery, and it has maintained that position despite the increased incidence of corneal melt associated with a generic version of the drug, according to Douglas A. Katsev, MD. He described diclofenac as a staple in his private practice in Santa Barbara, CA.
Read More
ESCRS to focus on four symposia during annual meeting
August 15th 2003Munich, Germany-The 2003 annual gathering of the European Society of Cataract and Refractive Surgeons (ESCRS) will open on Saturday, Sept. 6 and continue through Wednesday, Sept. 10, at the ICM Congress Centre, in this city in the heart of Bavaria.
Read More
IOL design mimics optic shape change of natural lens
August 1st 2003San Francisco-A novel accommodating IOL (FlexOptic, Quest Vision) designed to mimic the natural crystalline lens through an ability to change optic sphericity is a promising new alternative to treating presbyopia, with the potential for superior efficacy and safety relative to other options for surgical accommodative correction, said John D. Hunkeler, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Time-release drugs ease burden of drops
July 15th 2003San Francisco-Patient noncompliance can be overcome with the delivery of medication to the eye with intraocular time-release systems, according to James P. Gills, MD, who spoke during the Innovator's Session at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Silicone IOL well tolerated in high-risk glaucomatous eyes
July 1st 2003San Francisco-The ClariFlex third-generation silicone IOL (AMO) is well tolerated in high-risk glaucomatous eyes, and the Unfolder Silver-Z insertion system (AMO) performs well in these eyes, with a very low incidence of cartridge jams or damaged IOLs, accord-ing to Thomas W. Samuelson, MD.
Read More
IOL edge design helps to reduce capsulotomy rates at 1 year
July 1st 2003San Francisco-The Sensar IOL (AMO) with OptiEdge provides patients with excellent visual acuity, and after 1 year, it is associated with a higher incidence of clear posterior capsules and a lower rate of Nd:YAG capsulotomy compared with the parent model without OptiEdge, reported William J. Fishkind, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Blue-blocking lens performs like standard UV-absorbing model
July 1st 2003San Francisco-The AcrySof Natural IOL (Model SB30AL, Alcon), containing a covalently bonded, blue light-filtering chromophore (ImprUV), more closely mimics the light transmission spectrum of the precataractous adult human crystalline lens compared with standard UV-absorbing IOLs without any adverse effects on vision, said Paul H. Ernest, MD, at the American Society of Cata-ract and Refractive Surgery an-nual meeting.
Read More
Pseudoaccommodative IOL reduces aberration
July 1st 2003San Francisco-With its proprietary apodized diffractive technology, the AcrySof ReSTOR pseudoaccommodative IOL (Alcon) provides patients with excellent near and distance vision and only infrequently causes visual symptoms that are generally minimal and easily tolerated, said David Allen, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Bausch & Lomb to delay regulatory filing
June 15th 2003Rochester, NY-Bausch & Lomb will delay the regulatory filing for the intravitreal fluocinolone acetonide implant (Retisert), a treatment for diabetic macular edema (DME), for up to 3 years while the FDA reviews 12-month safety data of additional eyes treated with implants.
Read More